Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neochem Bio SolutionsNSE:NEOCHEM +2.42%18 EBITDA Margin % is 18.48% as of Mar. 2026, which is 32% above its 10-year median of 14.05. GuruFocus rates NSE:NEOCHEM with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,579 Chemicals companies, Neochem Bio Solutions ranks better than 80.49% on this metric.
Neochem Bio Solutions (NSE:NEOCHEM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neochem Bio Solutions EBITDA Margin % Related Terms
Neochem Bio Solutions EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neochem Bio Solutions's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neochem Bio Solutions EBITDA Margin % Chart
Neochem Bio Solutions Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
9.73
10.53
17.56
19.81
Neochem Bio Solutions Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
EBITDA Margin %
0.00
0.00
20.25
21.02
18.48
NSE:NEOCHEM vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, Neochem Bio Solutions's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neochem Bio Solutions EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Neochem Bio Solutions's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neochem Bio Solutions's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neochem Bio Solutions (NSE:NEOCHEM) has a EBITDA Margin % of 18.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neochem Bio Solutions and its competitors. This is 32% above median its historical median of 14.05. Over the past decade, Neochem Bio Solutions' EBITDA Margin % has ranged from 9.73 to 19.81. According to the industry distribution chart, Neochem Bio Solutions ranks #308 out of 1579 companies in the Chemicals industry, placing it in the top 19.5%.
Is Neochem Bio Solutions' EBITDA Margin % too high?
Neochem Bio Solutions' current EBITDA Margin % of 18.48% is 32% above median its 10-year median of 14.05. Over the past 10 years, this metric has ranged from a low of 9.73 to a high of 19.81. The Chemicals industry median EBITDA Margin % is 9.67. Neochem Bio Solutions' value of 18.48% is 91.1% above this industry median. Based on the distribution chart, Neochem Bio Solutions ranks #308 out of 1579 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Neochem Bio Solutions has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Neochem Bio Solutions' EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Neochem Bio Solutions ranks #308 out of 1579 companies for EBITDA Margin %. This places Neochem Bio Solutions in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.67. Neochem Bio Solutions' value of 18.48% is 91.1% above this benchmark. Historically, Neochem Bio Solutions' own EBITDA Margin % has ranged from 9.73 to 19.81 over the past decade. While the company's 10-year median is 14.05 vs. the industry median of 9.67, Neochem Bio Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.67, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neochem Bio Solutions's current EBITDA Margin % of 18.48% is 91.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neochem Bio Solutions and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neochem Bio Solutions's current EBITDA Margin % is 18.48%, which is 32% above median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neochem Bio Solutions stock overvalued right now?
Neochem Bio Solutions (NSE:NEOCHEM) has a current EBITDA Margin % of 18.48%. The current EBITDA Margin % is 18.48%, which is 32% above median its 10-year median of 14.05 and 91.1% above the Chemicals industry median of 9.67. Neochem Bio Solutions' overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neochem Bio Solutions (NSE:NEOCHEM), the current EBITDA Margin % is 18.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neochem Bio Solutions Ltd is a specialty performance chemical company. Its primary product segments such as Polymers, Surfactants, Silicones, and Esters & bio-based sustainable solutions. The products are essential and used in industries such as textile & garment washing, home & personal care (HPC), institutional and industrial cleaners, water treatment, paints and coatings, paper and pulp, construction, rubber and dyes and pigments.
18GF Score
Get the complete analysis for NSE:NEOCHEM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEOCHEM has been successfully added to your 
